Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1.38% is 91% above its 5-year average of -15.62%, near the high end of its 5-year range (-42.07%–7.42%).
393.53% below its 12-month average of 0.47%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.53%.
EBITDA MARGIN
-1.38%
EBITDA MARGIN AVG TTM
0.47%
EBITDA MARGIN AVG 3Y
-10.06%
EBITDA MARGIN AVG 5Y
-15.62%
EBITDA MARGIN AVG 10Y
-18.54%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-393.53%
CURRENT VS 3Y AVG
+86.28%
CURRENT VS 5Y AVG
+91.17%
CURRENT VS 10Y AVG
+92.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
iRhythm Technologies, Inc.
Market Cap
$3.62B
EBITDA Margin
-1.38%
TTM Avg
0.47%
3Y Avg
-10.06%
5Y Avg
-15.62%
Market Cap
$3.53B
EBITDA Margin
-70.74%
TTM Avg
-2343.52%
3Y Avg
-1340.84%
5Y Avg
-951.82%
Market Cap
$3.42B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.10B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.62B | -1.38% | 0.47% | -10.06% | -15.62% |
| CareDx, Inc (CDNA)vs › | $3.58B | -1.23% | 8.45% | -16.90% | -13.40% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.53B | -70.74% | -2343.52% | -1340.84% | -951.82% |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 10.88% | 18.32% | -3.89% | -19.05% |
| ICU Medical, Inc. (ICUI)vs › | $3.98B | 14.57% | 8.24% | 9.01% | 11.36% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.10B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| LivaNova PLC (LIVN)vs › | $4.17B | 17.39% | 15.89% | 7.31% | 2.27% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.11B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | -54.45% | -179.51% | -231.98% | -287.87% |
Gross Margin
71.5%
EBITDA Margin
-1.4%
Operating Margin
-1.2%
Net Margin
-1.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 0.53% |
| 2026-03-31 | -2.66% |
| 2025-12-31 | 7.42% |
| 2025-09-30 | 1.36% |
| 2025-06-30 | -4.29% |
| 2025-03-31 | -16.17% |
| 2024-12-31 | 1.53% |
| 2024-09-30 | -29.76% |
| 2024-06-30 | -11.20% |
| 2024-03-31 | -24.08% |
| 2023-12-31 | -24.69% |
| 2023-09-30 | -17.69% |
| 2023-06-30 | -11.03% |
| 2023-03-31 | -31.02% |
| 2022-12-31 | -14.10% |
| 2022-09-30 | -19.88% |
| 2022-06-30 | -18.41% |
| 2022-03-31 | -42.07% |
| 2021-12-31 | -33.48% |
| 2021-09-30 | -22.15% |
| 2021-06-30 | -16.20% |
| 2021-03-31 | -32.13% |
| 2020-12-31 | -7.70% |
| 2020-09-30 | -2.15% |
| 2020-06-30 | -33.42% |
| 2020-03-31 | -9.64% |
| 2019-12-31 | -25.44% |
| 2019-09-30 | -27.44% |
| 2019-06-30 | -11.28% |
| 2019-03-31 | -13.24% |
| 2018-12-31 | -25.38% |
| 2018-09-30 | -22.51% |
| 2018-06-30 | -31.36% |
| 2018-03-31 | -33.02% |
| 2017-12-31 | -35.94% |
| 2017-09-30 | -22.03% |
| 2017-06-30 | -23.41% |
| 2017-03-31 | -20.74% |
| 2016-09-30 | -14.64% |
| 2016-06-30 | -22.17% |
| 2016-03-31 | -36.13% |
| 2015-12-31 | -61.68% |
| 2015-09-30 | -57.52% |
| 2015-06-30 | -56.89% |
| 2015-03-31 | -56.89% |
| 2014-12-31 | -58.40% |
